Verona Pharma (NASDAQ:VRNA) Earns Buy Rating from HC Wainwright

Verona Pharma (NASDAQ:VRNA)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $36.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 25.13% from the company’s current price.

A number of other analysts have also weighed in on the stock. Canaccord Genuity Group upped their price target on shares of Verona Pharma from $35.00 to $37.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd. Truist Financial raised their price objective on shares of Verona Pharma from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Friday, June 28th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $36.00.

Verona Pharma Stock Up 0.0 %

VRNA opened at $28.77 on Tuesday. The stock’s 50 day moving average price is $26.21 and its 200 day moving average price is $19.30. The company has a debt-to-equity ratio of 0.72, a current ratio of 8.61 and a quick ratio of 8.61. The stock has a market cap of $2.34 billion, a P/E ratio of -37.36 and a beta of 0.44. Verona Pharma has a 12 month low of $11.39 and a 12 month high of $30.73.

Verona Pharma (NASDAQ:VRNA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.53). During the same quarter in the prior year, the business earned ($0.11) earnings per share. As a group, research analysts predict that Verona Pharma will post -2.07 earnings per share for the current year.

Institutional Trading of Verona Pharma

A number of hedge funds have recently modified their holdings of the business. CWM LLC purchased a new stake in Verona Pharma in the 2nd quarter worth about $29,000. EMC Capital Management acquired a new stake in shares of Verona Pharma during the second quarter worth approximately $38,000. Legato Capital Management LLC acquired a new stake in shares of Verona Pharma during the second quarter worth approximately $154,000. Marshall Wace LLP purchased a new position in Verona Pharma during the second quarter valued at approximately $195,000. Finally, Verus Capital Partners LLC acquired a new position in Verona Pharma in the 2nd quarter valued at approximately $251,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.